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 Abstract 
CAR-T cell therapy has achieved highly promising results in clinical trials, particulary 
in B-cell malignancies. However, reports of Serious adverse events (SAE) including 
a number of patient deaths has raised concerns about safety of this treatment. 
Presently available pre-clinical models are not designed for predicting toxicities seen 
in human patients. Besides choosing the right animal model, careful considerations 
must be taken in CAR T-cell design and the amount of T-cells infused. The 
development of more sophisticated in vitro models and humanized mouse models for 
preclinical modeling and toxicity tests will help us to improve the design of clinical 
trials in cancer immunotherapy. 
  
 Introduction 
The conventional treatment of cancer relies mostly on radiation, chemotherapy and 
surgery, which is successful in some patients but not all. Therefore, there is an 
unmet need to develop new approaches to treat cancer, such as immunotherapy. 
One exciting immunotherapeutic strategy entails the use of chimeric antigen receptor 
(CAR)-engineered T-cells. In this approach, T-cells isolated from patients are 
engineered to express an activating fusion receptor that binds directly to a cell 
surface target that is found on tumour cells alone, or also on healthy cell types that 
are dispensable or whose function can be replaced [1, 2]. 
Chimeric antigen receptors are classified based upon their signalling capabilities. 
First generation CARs contain a source of signal 1, most commonly TCR. While 
these have achieved some success pre-clinically [3], they have had limited impact in 
the clinical arena. Second generation CARs contain a single co-stimulatory module, 
most commonly derived from CD28 [4, 5] or 4-1BB [6] and which is placed upstream 
of TCR. Provision of co-stimulation enhances the target-dependent proliferation of 
CAR T-cells, potentiating their anti-tumour effect and prolonging their persistence in 
vivo [5, 7]. Second generation CARs directed against CD19 have achieved striking 
efficacy in the treatment of B-cell malignancy - most notably acute lymphoblastic 
leukaemia in which complete remission rates of 80-90% have been reported by 
independent centres using distinct CAR configurations [8-13]. Since CD19 antigen is 
also expressed on normal B-cells, it was predicted and subsequently confirmed that 
CD19-targeted CAR T-cells would commonly induce B-cell aplasia and 
hypogammaglobulinaemia – an on-target toxicity that can be managed effectively 
with the use of immunoglobulin replacement therapy. However, severe and 
sometimes unanticipated toxicities have also been reported, most notably in the form 
of Cytokine release syndrome (CRS) and neurotoxicity. 
 
The first detailed case report of CAR T-cell induced CRS involved a patient with 
metastatic ErbB2-expressing colon cancer. She received an intravenous infusion of 
10 billion 3rd generation CAR-T cells targeted against this naturally occurring 
receptor [14]. Within 15 minutes, the patient developed respiratory distress and 
progressed to cytokine release syndrome, multi-organ failure, repeated cardiac 
arrests and death 4 days later. Post mortem examination revealed that the toxicity 
may have resulted from binding to low levels of ErbB2 expressed on healthy lung 
parenchyma or endothelium [15]. 
A similar SAE was reported at the same time in a patient with chronic lymphocytic 
leukaemia (CLL) who received 3x107 2nd generation CAR-T cells targeting CD19 
[16]. In this case, it is possible that occult infection was a cofactor in the development 
of this event. In both of these patients, CAR T-cells were infused after 
lymphodepleting chemotherapy. 
 
 
 
 
 
 
Clinical experience of toxicity induced by CD19-targeted CAR T-cells 
 
More recently, as clinical experience with CD19-targeted CAR T-cells has grown, 
significant issues have been observed with toxicity due to CRS and neurotoxicities. 
CRS is a result of an overshooting and highly activated immune system [17]. The 
severity of CRS and the symptoms displayed can vary greatly [18]. The symptoms 
can include fever, vomiting, tachypnoea and tachycardia. Neurotoxicities can include 
headache, delirium, hallucinations and seizures. In general CRS and neurotoxicities 
are broadly defined as mild (grade 1), moderate (grade 2), severe (grade 3), life-
threatening (grade 4) and grade 5 which corresponds to the death of the patient [18]. 
Most clinical trials of CD19-targeting CAR T-cells running currently reported CRS 
and neurotoxicities (Table 1). Juno Therapeutics developed their anti-CD19 CAR T-
cell product to treat B-ALL and decided to halt their clinical trial due to the 
development of cerebral edema which led to the death of patients (Clinicaltrials.gov 
identifier: NCT02535364) (Crow, David. Juno shares tumble as cancer drug trial 
halted. The Financial Times Limited, 2017. Web. 23.11.2016). 
 
 
 
 
 
 
 
Affinity of CAR T-cells 
The CD19-targeting CAR T-cells used to treat the patient with CLL were designed 
with the scFv derived from the SJ25C1 hybridoma [3]. The anti-CD19 scFv from 
SJ25C1 does recognise the CD19-antigen, as assessed in a FACS competition 
assay [19]. In order to evaluate the affinity of the scFv from SJ25C1 the protein was 
iodinated and Scatchard analysis performed to evaluate binding parameters with its 
receptor. However, the specific affinity of scFv from SJ25C1 was too low to be 
determined, thus indicating that we are dealing with a low-affinity CAR-T cell 
construct.  
 
The role of affinity in CAR-mediated T-cell activation in response to their cognate 
antigen remains controversial. When the antigen was immobilised on a solid surface 
CAR-mediated T-cell activation was reported to be dependent on the strength of the 
interaction, because of the correlation between the affinity of different CAR T-cell-
constructs and IFN-release by the CAR T-cells [20] . 
In contrast, the co-culture of those different affinity CAR T-cell-constructs with 
tumour cell lines expressing the cognate antigen in different quantities revealed that 
effective lysis of the target cell was dependent on the amount of antigen expressed 
on the surface rather than the binding affinity of the scFv domain [20]. Furthermore, 
high affinity CAR T-cell constructs were less able to discriminate between tumour 
cells that express either high or low levels of antigen (Ag) on their surface [20]. The 
loss of selectivity can have fatal consequences when infused into patients, as 
healthy cells with a basal level of Ag-expression will be also eliminated along the 
cancerous cells with a high Ag-expression profile. However, not only the affinity of 
the scFv domain is important, the position of the targeted epitope within the antigen 
plays an important role in the activation of the CAR T-cell. This was shown with 
engineered immunoreceptors targeting the carcinoembryonic antigen (CEA) 
expressed on cancerous gastrointestinal cells which either targeted a domain distal 
or proximal from the cell membrane [21]. The proximally located scFv receptor 
elicited increased cytolysis and IFN- release in comparison to the distal location 
upon binding to its epitope, although the distal epitope binds with higher affinity. This 
suggests that there is for CAR T- cells an optimal distance for their interaction with 
their target, irrespective of their affinity. 
The structure of the CD19 antigen is currently unclear and, consequently, the binding 
of the CD19 scFv derived from the SJ25C1 hybridoma to its target is unknown and 
its interaction can merely be modeled [22]. 
 
CART-cell dose 
 
Another important aspect of CAR T-cell therapy is the quantity of T-cells infused into 
the patient. Some researchers are of the opinion that the infused dose does not 
correlate with SAEs or severe neurotoxicity although it has been reported that 
toxicities develop more often after the infusion of a high CAR T-cell dose [12, 23]. 
These neurotoxicities may be caused by CAR T-cells migrating into the brain 
because a higher CAR T-cell number was found in the Cerebrospinal fluid (CSF) of 
patients with severe signs of neurotoxicity [12]. This migration of CAR T-cells into the 
brain is not a surprise as the CSF of healthy individuals can contain up to 3000 
leukocytes per ml and drains into cervical lymphatics allowing the CAR T-cells to 
enter the brain and cause potential neurotoxicities [24]. In both reports of SAEs the 
patients received a high dose of CAR T-cells with 1010 and 3x107/kg respectively. 
Coming from the field of peptide immunotherapy the administered dose plays a huge 
role and as Paracelsus stated correctly: “The dose makes the poison”. A dose 
escalation is always recommended to identify the maximum tolerated dose and a 
successful dose escalation is able to prevent the development of adverse side 
effects in peptide immunotherapy [25]. The same principle was seen as the company 
Kite performed a dose escalation trial with their KTE-C19 product targeting 
haematological malignancies and observed dose-limiting toxicity with grade 3-4 CRS 
predominantly at a dose of 3x106/kg anti-CD19 CAR T-cells but not at the lower dose 
of 1x106/kg CAR T-cells [12]. 
However, even in a clinical trial conducted by Kite which is considered successful, 
evident by high overall response rates and high complete remission rates, patients 
developed serious side effects [26]. 
Kite target with their KTE-C19 product in the ZUMA-1 trial refractory aggressive non-
Hodgkin lymphoma (NHL) (trial number: NCT02348216). Recently published results 
reported safety, in vivo effects and efficacy of the ZUMA-1 trial [26]. Kite reported the 
development of adverse events after a CAR T-cell dose of 1-2x106 anti-CD19 CAR+ 
T-cells/kg. The majority of the patients experienced CRS and neurological toxicities 
of grade 3 or less but all treatment-related AEs were successfully managed within 30 
days. 
This trial used the monovalent scFv derived from the mouse hybridoma cell line 
FMC63 which binds the CD19+-target cell with an affinity constant of 2.3 x 10-9 M, 
which corresponds to a high-affinity interaction [27]. One could speculate that 
although a scFv domain with a high affinity was used, the lower dose of infused T-
cells prevented the death of patients in contrast to the trial initiated by the Memorial 
Sloan Kettering Cancer Center where 3x107 CAR-T cells were infused targeting 
CD19 using a scFv domain with low affinity. Differences in toxicities could be 
potentially induced by the usage of different co-stimulatory domains, although both 
studies used the signalling domain of the CD28 receptor, or the different retroviral 
vectors used for delivery. The safety of CD19 targeting CAR T-cells can also be 
influenced by a number of factors other than CAR T-cell design including the 
heterogeneity of the targeted disease and the age differences of the patient 
population. 
The balance between a successful anticancer response and the danger of eliciting 
serious toxicities seems precarious. Both studies tested their CAR T-cell constructs 
in mouse models beforehand, but these were xenograft models established in 
immunocompromised mice [28, 29]. 
 
 
 
 
 
 
 
 
 
 
 
Preclinical modeling 
 
Would it be possible to prevent the death of patients resulting from adverse effects of 
CAR T-cell therapy by using more sophisticated in vitro models and humanized 
mouse models for preclinical modeling and toxicity tests? 
 
Rather than requesting unreliable xenograft mouse model experiments, effort should 
be made to to develop animal models that reflect a human immune system more 
accurately. Mouse models can also help us to develop treatments for very rare 
diseases where the number of patients would otherwise be too low to initiate a 
clinical trial. 
 
The specificity of CAR T-cells and the different functional response is generally 
tested in vitro in cultures of monolayers of cells expressing the target antigen in 
comparison to cells that do not express the antigen. The development of organoids 
provides an important bridge between the traditional in vitro monolayer cell culture 
and the in vivo mouse/human models. Organoids are 3D organotypic cultures and 
represent ‘mini-organs’ in a dish [30]. Organoids can be derived from stem cells and 
exploit their intrinsic biological capability of self-organisation [31]. The cells are able 
to organise themselves between each other and also within the tissue which allows 
the development of a mini-organ reflecting the structure and functional properties of 
organs such as brain, lung or intestine [32]. In addition, organoids can also be 
generated from human cancer specimens like glioblastomas, colorectal tumours and 
pancreatic cancer and can recreate the histopathology seen in the primary tumour 
[33-36]. Of course, there are still limitations to the use of cancer organoids, such as 
the absence of cell interactions between the epithelia or stroma and the lack of an 
intact human immune system, which greatly affect disease progression. One study 
successfully grew cancer cells together with endothelial and stromal cells in a 2D 
culture [37]. It would be possible to overcome the potential limitations, such as the 
lack of stroma and the missing immune system, by culturing cancer organoids 
together with endothelial and stromal cells as a 3D model and then infuse those 
mini-organs into mice engrafted with a human immune system. This humanisied, 
patient-derived organoid model system would allow the investigation of the efficiacy 
of CAR T-cell therapy and also determine the immune responses elicited. 
 
Using mice as a model organism in research has helped us to develop treatments of 
severe diseases. The successful treatment of acute promyelocytic leukemia (APL) 
using a combination of retinoic acid and arsenic, which was mainly untreatable 
previously, was a direct result from pioneering work in mice [38]. This cancer, 
caused by gene fusions that affect the bone marrow, can now be treated after 
extensive research using genetically engineered mice (GEMMs) resembling different 
types of APL. In a similar vein, GEMMs bearing the human breast cancer gene 
BRCA1 mimicked features of the human breast cancer better than xenograft models 
and helped in defining a treatment using chemical inhibitors of poly-(ADP-ribose)-
polymerase-1, which delays the onset of resistense to the treatment [39]. 
 
Some researchers see mouse models just as a passport to be allowed to perform a 
clinical trial or are wary of possible adverse effects they might see in a mouse model, 
which could delay initiation of a clinical trial, even though these adverse effects may 
not necessarily represent the human situation. However, even though animal models 
are by no means perfect, sometimes seeing adverse side effects of the treatment in 
a mouse model can help in improving the design of a future human clinical trial. 
Work by our group showed that the treatment of SCID/Beige mouse with T4+ T cells 
a T1E28z second-generation CAR targeting ErbB-1 homodimers and ErbB2/3 
heterodimers resulted in severe toxicities dependent on the route of administration 
[40]. Tumour-bearing animals who received T4+ T cells either intravenously (i.v.) or 
intratumoural (i.t.) showed tumour regression with no sign of severe toxicities. T4+ T 
cells, which have been administered intraperitoneal (i.p.) have led to the rapid death 
of the animals caused by the induction of a CRS indicated by the upregulation of 
human IFN-, human IL-2 and mouse IL-6 in the serum of the animals. The severe 
on-target off-tumour toxicity seen may have been caused by ErbB1 expression by 
healthy mesodermal cells in the peritoneal cavity. This study demonstrated the 
importance of the route of administration and led to the initiation of a clinical trial 
treating patients with head and neck cancer by the infusion of T1E28z CAR T-cells 
i.t. [41]. 
 
Certainly, current mouse models have not always proven reliable as preclinical 
models in particular in CAR T-cell therapy of cancer. But this is mainly because the 
current available mouse models are imperfect and the improvement of mouse 
models would help us to generate knowledge that translates more directly to the 
human situation. The most common model used in studying cancer therapy is the 
xenograft model, established by either transferring cancer cell lines or patient-
derived tumours (PDX) into immune-deficient mice. It is clear that the assessment of 
CAR T-cell therapy using xenograft models without immune sytem components does 
not help us in gaining any further knowledge about how this T-cell construct might 
act in a human being.  
 
The efficacy of CAR T-cell treatment can also be better examined by the addition of 
other cell types into xenograft models, which are known to diminish the effect of CAR 
T-cells, such as regulatory T-cells (Tregs) or myeloid-derived suppressor cells 
(MDSC). In one study, carcinoembryonic antigen+ (CEA) C15A3 tumor cells were 
transferred into immunodeficient mice together with human Tregs, to investigate the 
efficiacy of tumour cell lysis by CEA-specific CAR T-cells [42]. CEA-specific 
CD3CAR T-cells were able to prevent tumour formation even in the presence of 
Tregs. However, the infusion of CD28-CD3 CAR T-cells led to a progressive tumour 
development in the presence of Tregs, even though the cytolytic efficiency assessed 
in vitro was the same for both T-cell constructs. Further analysis clarified that in this 
case the production of IL-2 by the CD28-TCRCAR T-cells after target engagement 
improved the survival of Treg cells. The subsequent introduction of a mutation in the 
lck binding domain of the CAR CD28 moiety to prevent IL-2 secretion led to a 
reduction of tumour-infiltrating Tregs and improved the anti-tumour response. The 
normally considered improved design of addition of the CD28-domain supported 
Treg development and abolished CAR T-cell efficiency in the model of CAR T/Treg-
cell co-transfer. 
In another immunocompetent murine model of CEA+ liver metastases (LM) anti-CEA 
CAR T-cell therapy was investigated under the influence of MDSCs [43]. Hepatic 
MDSC expanded more than 3-fold in response to LM. Mice with established LM 
received CEA CAR T-cells in combination with a MDSC depletion strategy, which led 
to a prolonged survival of the mice compared to CEA CAR T-cell treatment only. 
MDSC suppressed CAR T-cells via the expression of PD-L1 on their surface. When 
tumour-bearing animals received CEA CAR T-cell in combination with a PD-L1 
blocking antibody and a reduction in tumour burden could be detected compared to 
the treatment with the CAR T-cells only. 
 
 
A very good example of the need for better animal models to test T cell-mediated 
cancer immunotherapy is the use of the anti-cytotoxic T lymphocyte-associated 
molecule-4 (CTLA-4) antibody Ipilimumab for the treatment of melanoma. Before a 
clinical trial was initiated, Ipilimumab was used in studies to treat tumour models of 
fibrosarcoma and ovarian carcinoma in mice [44]. Blocking CTLA-4 in tumour-
bearing mice led to the development of anti-tumour T-cell responses and 
subsequently tumour regression. There were no adverse toxic effects nor any signs 
of the development of autoimmunity reported, which led to the initiation of a clinical 
trial. Patients with metastatic melanoma were treated with anti-CTLA-4, which 
resulted not only in tumour regression but also led concurrently to the development 
of severe autoimmune toxicities including colitis and dermatitis [45]. A later study 
used a humanized mouse model reconstituted with human HSCs, and anti-CTLA-4 
treatment could mirror the side effects seen in the clinical trial [46]. Ipilimumab-
treated humanized mice developed autoimmune hepatitis. Taken together it is 
important to test therapies in an appropriate mouse model to rule out unwanted 
severe side effects before initiating a clinical trial.  
 
It is beyond doubt that the mouse models come with many challenges: 
 Animals used in experiments tend to be rather young while many human 
cancers develop later in life. 
 maintenance of the animals happens in a clean and controlled environment 
and does not take environmental factors into account. 
 Animals are mostly inbred which does not take genetic variability of diseases 
into account. 
 Animal models do not reflect the patient situation with relapsed, refractory or 
resistant disease. 
 
 
 
 
 
 
 
 
Development of humanized mouse models 
 
One approach to model human cancer or to “humanize” mouse models is to 
genetically modify mice. In this way, human oncogenes are introduced into the 
mouse genome and tumour development can be observed as already mentioned.  
Another approach is to introduce human hematopoietic stem cells (HSCs) or 
peripheral blood mononuclear cells (PBMCs) into immunocompromised mice to 
create mice with a humanized immune system. Immunodeficient mice like those with 
severe combined immunodeficiency (SCID) support the engraftment of human 
peripheral blood leukocytes (PBLs) (Hu-PBL-SCID) and HSCs (Hu-SCR-SCID) cells 
[47-49] at a low level.  SCID mice have the disadvantage that their condition is 
“leaky” and can still generate a few functional T and B cell clones in addition to 
having no impairment in myeloid cell differentiation and natural killer cell (NK) activity 
[50]. The level of human cell engraftment was efficiently increased by crossing the 
SCID mouse with the nonobese diabetic mouse (NOD-SCID mice) because this 
mouse strain showed reduced levels of innate immune cells [51].  
 
The breakthrough in the field of human cell engraftment came with the creation of 
the NOD-SCID mouse with either a deletion of the IL-2R common chain (NSG 
mouse) or a truncated mutation of the IL-2R (NOG mouse), which both allow the 
engraftment of human cells to a previously unachievable level [52]. The NSG mouse 
was found to support greater engraftment of human cells than any of the other 
available strains [53]. Engraftment of HSCs allows the development of a multilineage 
immune system while the engraftment of peripheral blood mononuclear cells 
(PBMCs) represents an already matured immune system. The approach of 
transferring PBMCs into NSG mice only allows short-term experiments because the 
animals develop graft-versus-host disease (GvHD) within 4-5 weeks [54]. 
Furthermore, this NOD-scid IL2Rγnull mice engrafted with CD34+ HSCs develop a 
diverse TCR repertoire, have a prolonged life span and develop no graft-versus-host 
(GvH) disease [55]. The downside of this model is that the developing human T-cells 
in the thymus lack the ability of recognising antigens in an HLA-restricted manner 
because the murine thymic epithelium lacks the expression of HLA molecules. This 
limitation was overcome by the development of the NSG-HLA-A2/HHD strain 
expressing HLA class I heavy and light chains which led to differentiation of 
functional CD4+ and CD8+ T-cells able to secrete cytokines in vivo [56]. A third 
method for the generation of humanized mice is the bone-liver-thymus (BLT) model. 
In this model, foetal thymus and liver tissue are implanted beneath the renal capsule 
of the kidney along with the co-transfer of autologous CD34+ cells into an 
immunodeficient murine host [57, 58].  
The co-engraftment of thymic tissue and human hematopoietic stem cells in 
immunocompromised mice allows the development of human T-cells, which interact 
with human MHC molecules, able to mount an antigen-specific immune response. 
One of the main disadvantages of the BLT model is the development of GvHD 
affecting skin, lungs and the gastrointestinal tract, which limits the experimental 
window[59]. 
 
The further engraftment of humanized mice with human tumour cell lines allowed the 
investigation of the interaction of the tumour with the immune system [60]. In the 
humanized tumour mouse model (HTM), human CD34+ HSCs were co-transfered 
with human breast cancer cells into irradiated newborn NSG mice [60]. The mice 
developed a human immune system characterized by the presence of T-, B-, NK-
cells and macrophages besides the development of solid human breast cancer 
without eliciting any rejection caused by MHC-mismatched cells.  
 
The disadvantage of using cancer cell lines for engraftment is the loss of tumour 
heterogeneity and the molecular make-up that is clinically relevant. 
To further enhance the use of humanized mice in cancer immunotherapy the 
generation of humanized patient-derived xenograft tumour models (PDX) would be 
essential. This was achieved by the engraftment of irradiated NSG mice with in vitro 
expanded HSCs and the subsequently transplantation with a patient’s head and 
neck carcinoma sample, called xenochimeric mice (Xact mice) [61]. The tumour cell 
stroma of Xact mice contained human CD45+ CD151+ cells originating from the bone 
marrow of engrafted mice. Furthermore, the intra-tumoural lymphatic vasculature in 
Xact mice showed an increase in vessel density, suggesting that the Xact model is 
able to recreate the native tumour environment. 
 
Humanized mice cannot develop all characteristics of a human immune system. In 
particular, they lack innate immune cells due to the absence of human cytokine 
signaling and exhibit poor lymph node development [62]. Several strategies have 
been developed to overcome those limitations. Human cytokines were either 
delivered exogenously to humanized mice or knock-in models were developed 
where single human cytokine genes were introduced into the mouse genome, 
replacing the mouse cytokine gene [63-66]. All of those modifications improved the 
development of individual cell populations like human NK cells [63], human alveolar 
macrophages [65] or human monocytes [66] but did not result in a complete 
reconstitution of a human innate immune system. 
 
An attempt to express a range of human cytokine genes in order to enable complete 
innate immune cell development led to the generation of MITRG mice [67]. These 
mice harbor a knock-in of human M-CSF, IL-3/GM-CSF and human thrombopoietin 
(TPO) in their respective gene loci. Humanized MITRG mice develop functional 
myeloid cells, monocytes and NK cells. However, these mice allow human HSC 
engraftment to a great extent, which in turn leads to massive deficits in mouse red 
blood cells resulting in severe anemia and the death of the animals [67]. This just 
leaves a very short experimental window of approximately 2 to 3 weeks, which 
makes this model not ideal. 
 
As mentioned earlier humanized mice exhibit poor lymph node development. This 
obstacle could be overcome by a tissue engineering approach where artificial lymph 
nodes (LNs) could be generated in humanized mice. Lymph nodes as a secondary 
lymphoid organ (SLO) are important organs for T cell activation and the initiation of 
adaptive immunity [68]. Live in vivo two-photon imaging revealed that lymphocytes 
migrate into LNs and interact with antigen-presenting cells [69]. Tertiary lymphoid 
organs (TLOs), which can develop at sites of inflammation anywhere in the body, 
share the same function as SLOs [70] and are very similar in their organizational 
structure [71]. The successful engineering of artificial lymph node-like tertiary 
lymphoid organs (artTLOs) showed that these artificial structures are transplantable 
and retain their immunological function [72-74]. The newest approach from the 
Watanabe lab is a stromal cell-free model where slow-releasing gel-beads containing 
a chemokine cocktail, lymphotoxin-12 and soluble RANK ligand (sRANKL) are 
embedded in a collagen sponge [75]. This collagen sponge was then transplanted 
into the subcapsular space of the kidney of mice. After 3 weeks, immunological 
active artTLOs have been formed. This tissue engineering approach could be used 
to create human artTLOs by transplanting those collagen sponges into humanized 
mice. 
 
Another approach to test CAR T-cell therapy is by using humanized mouse models 
where human tumours are generated de novo alongside the development of a 
matched human immune system. A human mixed-lineage-leukemia (MLL) model 
was developed by transduction of CD34+ HSC with the oncogene MLL-AF10 along 
with the gene for K-ras and transfer into NOG mice which led to the development of 
acute monoblastic leukemia [76]. The strength of this approach is the ability to study 
the steps of human tumourigenesis including initiation, development and 
dissemination of cancer alongside the development of a matched human immune 
system.  
The use of a humanized mouse model of treatment refractory B-cell leukemia 
showed that tumour cells in the bone marrow were resistant to treatment with the 
anti-CD52 antibody alemtuzumab [77, 78]. Combination therapy using alemtuzumab 
and the chemotherapeutic agent cyclophosphamide led to a near complete 
elimination of the disease in the bone marrow. Furthermore, the initial dose of the 
toxic cyclophosphamide could be reduced by a third and still resulted in disease 
elimination to the same extent. Very recently, a humanized mouse model of 
spontaneous B-cell acute lymphoblastic leukemia (B-ALL) was developed [79]. 
Human foetal thymic tissue (FTHY) and liver plus CD34+ HSCs transduced with the 
oncogene MLL-AF9 were transplanted into irradiated NSG mice, which led to the 
development of human T -, B and myeloid cells as well as leukemic cells which 
makes this model system superior to other available models evaluating cancer 
immunotherapy using anti-CD19 CAR T-cells. 
 
Conclusion 
 
CAR T-cell therapy, especially in B-cell malignancies, has delivered impressive and 
promising results in the treatment of haemotological cancer. It is a balancing act to 
design improved CAR T-cells for successful tumour elimination while also limiting the 
development of serious adverse effects. In CAR T-cell design, there does not seem 
to be a consensus or rule that defines the best scFv targeting domain or signaling 
domain, resulting in diverse clinical trials targeting the same antigen. Predicting CAR 
T-cell toxicities that result from their activation, using existing preclinical models, is 
still in its infancy. Current preclinical models are mostly unable to recapitulate the 
severe toxicities seen in human clinical trials after CAR T-cell infusion. Testing CAR 
T-cells for their suitability in the clinic implies the use of immuno-compromised 
mouse models. Mostly, immuno-compromised animals are challenged with human 
tumours where the antigen targeted by the CAR T-cells is exclusively expressed on 
the tumour cell preventing the development of potential on-target, off-tumour 
toxicities. 
In reality, clinical trials have been initiated without the input from valuable preclinical 
mouse models that could have aided in improving their design. But, following reports 
of deaths in clinical trials, the scientific community tries to improve their 
understanding of mechanism leading to toxicities by developing new murine 
humanized cancer models (summarized in Table 2). 
 
Future perspective 
Several new strategies are in place and will be exploited to create better preclinical 
murine models to hopefully further reduce treatment-related toxicities in the future 
(Figure 1). Validated humanized mouse models hold great promise for improving 
safety of CAR T-cell therapy. The challenge to develop these chimeras, which are 
viable enough to provide a healthy environment for the transplanted human cells to 
thrive in while at the same time limiting the development of GvHD, is also strongly 
dependent on future developments in stem cell research and tissue engineering. 
However, recent successes in developing improved preclinical humanized tumour 
mouse models represent a step in the right direction. Further developments over the 
years to come are likely to provide new models that will allow for accurate modelling 
of CAR T cell therapy in vivo, thus accelerating clinical translation of new strategies, 
while limiting devastating adverse effects. 
Executive summary 
 
 Despite promising results in CAR-T cell therapy, reports of SAEs in 2010 
raised concerns about safety. 
 The majority of anti-CD19 CAR T-cell clinical trials reported CRS and 
neurotoxicities. 
 The choice of the scFv for the CAR-T cell defines the affinity of the CAR-T cell 
construct and can affect their efficacy. 
 Infusion of high CAR-T cell doses correlates with incidence of severe 
toxicities. 
 Current preclinical models are unable recapitulate toxicities seen in patients. 
 Cancer organoids could provide a bridge between traditional monolayer cell 
culture and in vivo models. 
 Humanized mouse models were developed by engraftment of CD34+ HSCs 
into immunodeficient mice. 
 Humanized mouse models are further advanced by co-engraftment of human 
tumour cell lines or patient-derived tumour samples. 
 Humanized mice still exhibit deficits in the development of a complete human 
immune system. 
 Expression of various human cytokines in humanized mice enables 
development of innate immune cells. 
 Poor lymph node development in humanized mice could be overcome by a 
tissue engineering approach. 
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Table 1: Anti-CD19 CAR T-cell clinical trials and their reported toxicities. 
 
Institution 
 
 
Ref. 
 
Disease 
 
No.  
patients 
 
Toxicities 
 
Clinicaltrials.gov 
identifier 
 
Memorial Sloan 
Kettering 
Cancer Center 
 
[80] 
 
B-ALL 
 
46 
 
n=11 with severe CRS; 
n=13 with neurotoxicity 
grade 3-4 
 
NCT01044069 
[81] CLL 8 most patients with mild 
CRS 
NCT00466531 
[82] CLL 8 n=4 with mild CRS NCT01416974 
[83] B-NHL 8 n=4 with CRS NCT01840566 
 
University of 
Pennsylvania 
 
[84] 
 
CD19+ ALL 
 
59 
n=52 with CRS; 
n=16 with severe CRS 
NCT01626495 
[85] CD19+ ALL n=27 n=21 with CRS grade 3 or 
greater; 3 deaths due to 
CRS 
NCT02030847 
[86] CLL n=35 n=19 with CRS; 
n=7 with CRS grade 3 or 
greater 
NCT01747486 
[87] B-NHL n=29 Not reported NCT02030834 
[88] multiple 
myeloma 
n=10 n=1 with CRS grade 1 NCT02135406 
 
Fred 
Hutchinson 
Cancer 
Research 
Center 
 
[89] 
 
CD19+ ALL 
 
n=36 
 
Not reported 
 
NCT02028455 
[90] B-ALL 
B-NHL 
CLL 
n=90 n=14 with severe CRS; 
n=3 with CRS grade 4; 
n=27 with neurotoxicities 
grade 3 or greater, 4 
deaths due to CRS 
NCT01865617 
 
National 
Cancer Institute 
 
[12] 
 
B-ALL 
B-NHL 
 
n=21 
 
n=3 with CRS grade 4 
 
NCT01593696 
[91] B-NHL n=22 Not reported NCT00924326 
 
City of Hope 
Duarte 
Comprehensive 
Cancer Center 
 
[92] 
 
B-NHL 
 
n=8 
 
No toxicties of grade 2 or 
greater 
 
NCT01318317 
[92] B-NHL n=8 no tocixities of grade 2 or 
greater 
NCT01815749 
 
Kite Pharma 
 
[26] 
 
B-NHL 
 
n=7 
 
n=3 with CRS grade 3; 
n=3 with CRS grade 4 and 
neurotoxicity; n=1 with 
CRS grade 4 and 
neurotoxicity 
 
 
NCT02348216 
ALL = acute lymphoblastic leukemia; CLL = chronic lymphocytic leukemia; B-NHL = B-cell non-Hodgkin 
lymphoma; CRS = cytokine release syndrome  
 
 
 
 
Table 2: Examples of preclinical humanized tumour models. 
 
Category Model Characteristics Ref 
Humanized tumour 
mouse model 
Cotransfer of human HSC and 
human Her2 overexpressing breast 
cancer cells into NSG mice 
Presence of human T-, 
B-, NK-cells and 
macrophages and solid 
breast cancer 
60 
Humanized PDX 
tumour model 
Xact mice 
Transfer of ex vivo expanded human 
HSC and transplantation with human 
PDX from head and neck carcinoma 
Tumour stroma is 
infiltrated with human B- 
and T-cells and increase 
in intra-tumoural vessel 
density 
61 
Humanized de 
novo tumour 
mouse models 
MLL model 
Transfer of human HSC transduced 
with oncogene MLL-AF10 and K-ras 
into NOG mice 
 
MYC/BCL2 (hMB )-model  
Transfer of human HSC transduced 
with oncogene Bcl-2 and c-Myc into 
NSG mice 
 
BLT B-ALL model 
Cotransfer of foetal thymic and liver 
tissue and human HSC transduced 
with oncogene MLL-AF10 into NSG 
mice 
 
Development of acute 
monoblastic leukemia 
 
 
 
Development of 
refractory B-cell 
leukemia 
 
 
 
Presence of human T-, B 
and myeloid cells and 
leukemic cells 
76 
 
 
 
 
 
78 
 
 
 
 
 
79 
 
HSC = Hematopoetic Stem Cells; ALL = Acute Lymphoblastic Leukemia; PDX = Patient-Derived 
Xenograft; MLL = Mixed Lineage Leukemia; BLT = bone marrow-liver-thymus 
 
 
  
 Figure 1: Future of preclinical models testing CD19-targeting CAR T-cells. A 
Humanized mouse models with components of the human immune sytem were 
developed by the transfer of human stem cells (HSCs) into immunocompromised 
mice. The further subsequent engraftment with human tumour cell lines (C), tumours 
from human patients (D) or cancer organoids (E) will improve pre-clinical modelling 
and predicting CAR T-cell toxicities. Humanized mouse models lack the 
development of lymph nodes, which could be overcome by implanting artificial lymph 
nodes (F). B The co-transfer of HSCs and tumour cell lines into immune-
compromised mice allows the simultaneously development of a human immune 
sytem and solid cancer. 
 
